Remember very well another time they published, almost to the word, similar, quite irrelevant , to be polite, when it comes to a biotech company," analysis". It was for PCYC,which was at the time at $20+., about year ago.
This rating is a big laugh. All they want to do is prey on the small investor. They want you to buy their Tout sheet. That's how they make money. Don't be fooled by fools. Good luck.
Sentiment: Strong Buy
What a bizarre downgrade. Talking about ACAD like it's an electric utility instead of a speculative biotech. Where do these people come from? Crazy stuff.
If this isn't a buy signal, I don't know what is.